Navigation Links
A ray of hope in Angioplasty dilemma

A new technique to keeping heart arteries flowing easily after angioplasty shows fantastic success in early testing, visibly solving a major weakness of the common procedure.Doctors released the longest follow up with the new technique - the drug-coated stent. In testing on 30 patients over three years, they found it to be 100 percent effective, an accomplishment almost unheard of in medicine.//

More than 1 million Americans undergo angioplasty annually, and the new approach is likely to be used on most of them if these promising early results hold up in further testing. They could be on the market as early as next year.// During angioplasty, doctors fish tiny balloons through clogged heart arteries, then inflate them briefly to open up blood flow. Frequently, though, the arteries squeeze shut again. In recent years, doctors have often left behind tiny wire coils, called stents, to prop the arteries open.

However, about one-quarter of the time, the reopened artery closes off, a condition called restenosis. It usually occurs when fast-growth scar-like tissue fills the artery, and it must be fixed with a repeat angioplasty or a coronary bypass.

The solution to this dilemma appears to be a new kind of stent that is coated with medicines that gradually ooze into the artery. The drugs keep cells from growing. At least eight different varieties - coated with different growth-inhibiting medicines - are now in testing, and many more are under development. The first was Cordis Corp.'s stent coated with the immune suppressing drug rapamycin, tested on patients in Brazil and the Netherlands.

Dr. J. Eduardo Sousa of the Dante Pazzanese Institute of Cardiology in Sao Paulo presented two years of follow up with those 30 initial patients. While three of them have needed heart procedures for worsening disease in other parts of their hearts, all of the areas treated with the Cordis stents are flowing freely. Sousa projected an X-ray of o ne of the patient's hearts, showing a wide, obstruction-free artery. ``No lesion. No problem,'' he said. ``The artery is completely open after two years follow up.''

Dr. Jean Fajadet of Thoraxcenter in Rotterdam gave results with the same stent after seven months in 238 patients. Again, not a single stent clogged up, compared with restenosis in 26 percent of those getting ordinary stents.

Dr. Sidney Smith, chief medical officer of the American Heart Association, cautioned that large, careful studies must be finished comparing the new stents with the ordinary kind. Nevertheless, he said, ``these are very impressive and very encouraging results. When you see zero restenosis at one year, it's a breakthrough. It's almost too good to believe when you see zero.''

Especially encouraging, Smith said, is the fact they seem to work in unusually small arteries and in those of diabetic patients. Both are very prone to reclogging. Dr. Greg Stone of Lenox Hill Hospital in New York City said the first of these stents could be available in 2003. Results of at least three large studies, necessary to win Food and Drug Administration approval, are expected on rival products within the next year.


'"/>




Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. Angioplasty death risk reduced by doubling drug dose
7. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
8. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
9. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Togadiyas Condition Stable After Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... 2016 , ... Augustine Insurance Agency, a locally owned and ... in the greater Dallas metropolitan area, is announcing a charity event that promises ... in 2009 by active police professionals in the Dallas region, the Dallas Fallen ...
(Date:12/7/2016)... Grants Pass, OR (PRWEB) , ... December 07, 2016 , ... ... Power of Water, Global Climate Change and Your Health on Voice of America, declared ... bullying, and to call attention to the fact that when these bullies attack leaders ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 ... Winner in the Folio: Marketing Awards competition. Live From won in the Use ... pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most innovative ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... Dec. 6, 2016  Viking Therapeutics, Inc. ("Viking") ... company focused on the development of novel therapies ... the U.S. Food and Drug Administration (FDA) has ... treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a ... that selectively regulates the expression of genes believed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
Breaking Medicine Technology: